August 20, 2014 8:27 PM ET

Healthcare Equipment and Supplies

Company Overview of eNeura Therapeutics LLC

Company Overview

eNeura Therapeutics LLC, a medical technology company, provides portable non-invasive Transcranial Magnetic Stimulation (TMS)/SpringTMS, a migraine system device for the treatment of migraine. The company was formerly known as Neuralieve, Inc. and changed its name to eNeura Therapeutics LLC on November 7, 2012. eNeura Therapeutics LLC was founded in 2000 and is based in Sunnyvale, California.

240 North Wolfe Road

Sunnyvale, CA 94085

United States

Founded in 2000



Key Executives for eNeura Therapeutics LLC

Chief Executive Officer
Founder and Director
Age: 85
Chief Financial Officer
Vice President of Marketing
Compensation as of Fiscal Year 2014.

eNeura Therapeutics LLC Key Developments

eNeura, Inc. Receives FDA Clearance for SpringTMS(R) Migraine Treatment Device

eNeura Inc. announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its SpringTMS(R) migraine treatment device. SpringTMS is the first medical device available to patients in the United States for the acute treatment of pain associated with migraine headache with aura. SpringTMS is a prescription-only device that utilizes single-pulse Transcranial Magnetic Stimulation (sTMS) to induce very mild electrical currents that can depolarize neurons in the brain. This process is thought to interrupt the abnormal hyperactivity associated with migraine. The non-invasive, proprietary device is designed for patient use. To treat, the device is placed at the back of the head where the push of a button generates a focused magnetic pulse with the intent to eliminate the pain of a migraine headache. SpringTMS provides the same therapy as the Cerena device but offers improved portability. The initial U.S. availability of SpringTMS will be launched at a select number of U.S. specialist headache centers.

eNeura Inc. Files 510(K) with FDA for SpringTMS(R) Migraine Treatment

eNeura Inc. announced that it filed a 510(k) with the U.S. Food and Drug Administration for the SpringTMS(R) transcranial magnetic stimulation (TMS) device. SpringTMS is a second-generation medical device based on company's CerenaTMS(TM), which recently received FDA clearance for the treatment of pain caused by migraine headaches preceded by an aura: a visual, sensory or motor disturbance immediately preceding the onset of a migraine attack. SpringTMS is more patient-friendly and portable compared to the previous generation device, and is already CE Marked in Europe and available by prescription in the UK. The user applies TMS to the back of the head using both hands and presses a button to generate a focused, single pulse of magnetic energy that treats the migraine headache non-invasively and without discomfort.

Similar Private Companies By Industry

Company Name Region
MedicaMetrix, Inc. United States
AeroCare Holdings, Inc. United States
EZ Way, Inc. United States
Vital Access Corp. United States
Element Science, Inc. United States

Recent Private Companies Transactions

Private Placement
February 10, 2014
Private Placement
December 27, 2013
Private Placement
September 20, 2013

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact eNeura Therapeutics LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at